Alnylam

Alnylam Pharmaceuticals Is Launched and Ready for More
Alnylam Pharmaceuticals Is Launched and Ready for More
Motley Fool
Alnylam
ATTR amyloidosis
Onpattro
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Alnylam CEO talks politics, gene therapy and not becoming Pfizer
Alnylam CEO talks politics, gene therapy and not becoming Pfizer
BioPharma Dive
Alnylam
RNAi
Onpattro
Pharma CEOs
John Maraganore
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst
Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst
Fierce Pharma
Alnylam
RNAi
Onpattro
hATTR amyloidosis
Flag link:
Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug
Alnylam shares drop 1.8% on new FDA approval strategy for rare disease drug
Marketwatch
Alnylam
FDA
givosiran
acute hepatic porphyria
Flag link:
FDA clears rare disease therapy from Akcea, Ionis
FDA clears rare disease therapy from Akcea, Ionis
Biopharma Dive
FDA
Akcea
Ionis Pharmaceuticals
Tegsedi
Onpattro
Alnylam
hATTR amyloidosis
Flag link:
Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial
Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial
Pharmaceutical Business Review
Alnylam
RNAi
ALN-AAT02
MHRA
UK
Flag link:
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
CP Wire
Alnylam
Patisiran
Onpattro
Japan
hATTR amyloidosis
Flag link:
Alnylam, with positive data on second gene-silencing drug, plans filing to FDA
Alnylam, with positive data on second gene-silencing drug, plans filing to FDA
Stat
Alnylam
gene-silencing
givosiran
FDA
acute hepatic porphyrias
Flag link:
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
CP Wire
Alnylam
Patisiran
hATTR amyloidosis
Onpattro
Flag link:
Alnylam Announces Encouraging Exploratory Cardiac Endpoint Data For Patisiran in hATTR Amyloidosis
Alnylam
hATTR amyloidosis
Patisiran
Flag link:
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
BioSpace
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
Flag link:
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
Motley Fool
Alnylam
Onpattro
Pfizer
ATTR amyloidosis
tafamidis
Vyndaqel
Flag link:
2 Blockbuster New Drug Launches Making Investors Nervous Right Now
2 Blockbuster New Drug Launches Making Investors Nervous Right Now
Motley Fool
drug launches
Alnylam
GW Pharma
Onpattro
Epidiolex
Flag link:
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
Motley Fool
Alnylam
Onpattro
hATTR amyloidosis
drug pricing
labeling
Flag link:
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
Motley Fool
Alnylam
FDA
Onpattro
hATTR amyloidosis
Flag link:
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
Motley Fool
Alnylam
Onpattro
RNAi
Flag link:
After Alnylam’s solo maiden launch, here comes the tricky bit
After Alnylam’s solo maiden launch, here comes the tricky bit
EP Vantage
Alnylam
drug launches
FDA
RNAi
Patisiran
Onpattro
Flag link:
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Forbes
Alnylam
FDA
drug pricing
hATTR amyloidosis
Onpattro
Flag link:

Pages